Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]

Core Viewpoint - The company, Dabo Medical, reassured investors that its operational status is normal despite recent stock price declines and shareholder reductions [1] Group 1 - Dabo Medical addressed investor concerns regarding the continuous decline in stock price and shareholder reductions [1] - The company confirmed that its operational situation remains stable and expressed gratitude for investor attention [1]

Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

Core Insights - The Biotech Index (970038) closed at 2182.31 points, down 0.94%, with a trading volume of 13.462 billion yuan and a turnover rate of 1.08% [1] - Among the index constituents, 7 stocks rose while 42 stocks fell, with Xinlitai leading the gainers at 0.83% and Hualan Biological leading the decliners at 5.98% [1] Index Constituents Summary - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 12.58%, latest price at 204.81, and a decline of 0.92% [1] - Changchun High-tech (sz000661) with a weight of 4.87%, latest price at 102.32, and a decline of 0.27% [1] - Shimeiao (sz002252) with a weight of 4.74%, latest price at 6.70, and a decline of 0.30% [1] - Kanglong Chemical (sz300759) with a weight of 4.55%, latest price at 29.16, and a decline of 1.22% [1] - Tigermed (sz300347) with a weight of 4.54%, latest price at 52.37, and a decline of 2.44% [1] - Shenzhen Technology (sz000021) with a weight of 4.16%, latest price at 23.90, and a decline of 1.77% [1] - Muyuan Foods (sz002714) with a weight of 3.62%, latest price at 48.45, and a decline of 0.31% [1] - Lepu Medical (sz300003) with a weight of 3.19%, latest price at 16.11, and a decline of 1.29% [1] - Aimeike (sz300896) with a weight of 3.16%, latest price at 155.51, and an increase of 0.58% [1] - Yuyue Medical (sz002223) with a weight of 3.07%, latest price at 35.28, and a decline of 0.20% [1] Capital Flow Analysis - The Biotech Index constituents experienced a net outflow of 1.382 billion yuan from major funds, while retail investors saw a net inflow of 1.358 billion yuan [1] - Notable capital flows include: - Aimeike (sz300896) had a net inflow of 26.5772 million yuan from major funds, but a net outflow from retail investors of 20.4422 million yuan [2] - Changchun High-tech (sz000661) saw a net inflow of 8.8418 million yuan from major funds, with a slight net inflow from retail investors of 186.25 thousand yuan [2] - Other stocks like Furuisi (sz300049) and Yuyue Medical (sz002223) also showed mixed capital flows with significant net outflows from retail investors [2]

大博医疗科技股份有限公司 证券代码：002901 证券简称：大博医疗 公告编号：2025-052 大博医疗科技股份有限公司（以下简称"公司"）第三届董事会已于 2025 年 10 月 27 日任期届满。鉴于公司新一届董事会换届工作尚在积极筹备中，为确 保公司董事会相关工作的连续性及稳定性，公司董事会的换届选举工作将适当延 期，公司董事会各专门委员会、高级管理人员的任期亦将相应顺延。 在新一届董事会换届选举完成前，公司第三届董事会成员、董事会各专门委 员会委员及高级管理人员将依照法律法规和《公司章程》等相关规定继续履行相 应的职责和义务。公司延期换届不会影响公司的正常生产经营，公司将积极推进 董事会换届工作，并按照相关规定及时履行信息披露义务。 特此公告。 大博医疗科技股份有限公司 关于董事会延期换届的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 董事会 2025 年 11 月 19 日 1 ...

证券代码：002901 证券简称：大博医疗 公告编号：2025-051 大博医疗科技股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议的召开和出席情况 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议召开时间：2025 年 11 月 18 日（星期二）下午 15:00 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 11 月 18 日 上午 9:15-9:25、9:30-11:30，下午 13:00-15:00。 ②通过深圳证券交易所互联网投票系统投票的开始时间为 2025 年 11 月 18 日上午 9:15 至下午 15:00 期间的任意时间。 2、会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式召 开。 3、会议召集人：公司董事会 4、会议主持人：公司董事长林志雄先生主持会议。 1 5、现场会议地点： 厦门市海沧区山边洪东路 1 ...

福建信实律师事务所 关于 大博医疗科技股份有限公司 2025 年第二次临时股东大会 之 福建信实律师事务所 中国·厦门市思明区湖滨南路 334 号二轻大厦 9 层 电话/Tel：86 592 590 9988 传真/Fax：86 592 590 9989 www.lhxs.com 厦门湖滨南路 334 号二轻大厦 9 楼 邮编 361001 电话 +86 592 5909988 传真 +86 592-5909989 www.lhxs.com 福建信实律师事务所 关于大博医疗科技股份有限公司 2025 年第二次临时股东大会之 法 律 意 见 书 致：大博医疗科技股份有限公司 福建信实律师事务所(以下简称"本所")受大博医疗科技股份有限公司(以下 简称"公司")的委托，指派吴上烁律师律师、周雨萌律师 (以下简称"本所律 师")出席公司于2025年11月18日召开的公司2025年第二次临时股东大会(以下简 称"本次股东大会")。本所律师根据《中华人民共和国公司法》(以下简称"《公 司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、《上市公司股 东会规则》(以下简称"《股东会规则》")、《深圳证券交易所 ...

Core Viewpoint - Dabo Medical has shown a significant increase in stock price and financial performance, indicating strong growth potential in the medical device sector [1][2]. Financial Performance - For the period from January to September 2025, Dabo Medical achieved a revenue of 1.876 billion yuan, representing a year-on-year growth of 22.69% [2]. - The net profit attributable to shareholders for the same period was 425 million yuan, reflecting a substantial year-on-year increase of 77.03% [2]. - Cumulative cash dividends since the A-share listing amount to 1.442 billion yuan, with 307 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 14, Dabo Medical's stock price rose by 2.02% to 50.56 yuan per share, with a market capitalization of 20.933 billion yuan [1]. - The stock has increased by 66.60% year-to-date, with a recent 3.10% rise over the last five trading days [1]. - The company experienced a net inflow of main funds amounting to 1.8528 million yuan, with significant buying activity from large orders [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 17.38% to 22,800, while the average number of tradable shares per person decreased by 14.80% to 12,673 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited being the fifth largest, increasing its holdings by 6.6836 million shares [3].

Group 1 - The stock price of Dabo Medical (002901) closed at 49.25 yuan on November 10, 2025, with an increase of 0.43% and a trading volume of 14,700 shares, resulting in a transaction amount of 72.50 million yuan [1][2] - On November 10, the net outflow of funds from major investors was 2.05 million yuan, while retail investors saw a net inflow of 4.86 million yuan [2] - The first exercise period of the 2024 stock option incentive plan was completed, with 643 participants exercising a total of 2.1559 million shares, accounting for 0.52% of the company's total share capital, at an exercise price of 23.39 yuan per share [1][2] Group 2 - The shares from the stock option plan will be listed and tradable starting November 7, 2025, and the company has completed the necessary procedures for the exercise [1][2]

Core Points - The stock of Dabo Medical (002901) closed at 49.25 yuan on November 10, 2025, marking a 0.43% increase from the previous trading day, with a total market capitalization of 20.39 billion yuan [1] - The company announced that the first exercise conditions of the 2024 stock option incentive plan have been met, allowing 643 participants to exercise a total of 2.1559 million shares, which represents 0.52% of the total share capital [1] - The exercise price for the stock options is set at 23.39 yuan per share, with the shares sourced from A-shares repurchased from the secondary market [1] Trading Information - On the day of the report, Dabo Medical opened at 48.99 yuan, reached a high of 49.43 yuan, and a low of 48.83 yuan, with a trading volume of 72.5032 million yuan and a turnover rate of 0.51% [1] Stock Option Plan - The stock options will be exercised in a centralized manner, and the shares will be listed for trading starting November 7, 2025 [1] - The company has completed the necessary procedures for the stock option exercise, and the total number of shares remains unchanged, maintaining compliance with listing conditions [1]